Unibest

Pharmaceutical intermediates

Bosutinib Intermediates

2 pharmaceutical intermediates for Bosutinib. Indication: Chronic myeloid leukemia; Chronic myelomonocytic leukemia; Myeloid leukemia acceleration; Blast cell crisis.

提交项目All intermediates

About Bosutinib

Originator
Pfizer Inc
Indication
Chronic myeloid leukemia; Chronic myelomonocytic leukemia; Myeloid leukemia acceleration; Blast cell crisis
Approved Date
09/04/2012
DS/DP
12/11/2025

Available intermediates

2 intermediates currently listed for Bosutinib. Request specifications, documentation or a quotation for any item below.

Bosutinib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
4-Chloro-7-(3-chloropropoxy)-6-methoxyquinoline -3-carbonitrile214470-68-5//
2,4-Dichloro-5-methoxyaniline98446-49-2//

Other programs under B

Baloxavir MarboxilBaricitinibBDTX-1535Bedaquiline FumarateBelumosudil mesylateBelzutifanBempedoic acidBeraprost Sodium

Building toward Bosutinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →